Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

In VivoSelection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model

(2015) S. Hendrickx et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh

(2015) Emiliano Lucero et al.   PLoS Neglected Tropical Diseases

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India

(2014) Sakib Burza et al.   PLoS Neglected Tropical Diseases

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study

(2013) Dinesh Mondal et al.   Lancet Global Health

Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use

(2012) S. Sundar et al.   CLINICAL INFECTIOUS DISEASES

Leishmaniasis Worldwide and Global Estimates of Its Incidence

(2012) Jorge Alvar et al.   PLoS One

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

(2012) Vasundhra Bhandari et al.   PLoS Neglected Tropical Diseases

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent

(2010) Filip Meheus et al.   PLoS Neglected Tropical Diseases